Coca-Cola Enterprises' (CCE) fiscal 2000 earnings estimates were lowered to 50 cents from 68 cents a share at UBS Warburg Dillon Read. Its fiscal 2001 estimate was lowered to 70 cents from 90 cents.
lowered the company's fiscal 2000 estimate to 45-50 cents a share from 68 cents and for fiscal 2001 to 65 cents from 95 cents a share. Merrill also downgraded the company's intermediate-term rating to neutral from buy.
: fiscal 2000 estimates UP to $5.05 from $4.25 at
Credit Suisse First Boston
; fiscal 2001 estimates UP to $7.10 from $6.10.
: NEW buy at
Donaldson Lufkin & Jenrette
; price target of 40.
: NEW intermediate accumulate, long-term buy rating at Merrill Lynch.
: NEW strong buy at
UBS Warburg Dillon Read
; price target of 65.
upgraded the following biotech stocks:
- Genzyme Molecular (GZMO) : NEW strong buy ;price target: 25.
Genzyme Transgenics (GZTC) : NEW strong buy; price target: 28.
Millennium Pharmaceuticals (MLNM) : NEW strong buy.
upgraded the following retail stocks:
started the following HMOs with strong buy ratings: